The Relationship of Baseline and Longitudinal Frailty and Inflammatory Biomarkers with CAR-T Treatment Outcomes in Relapsed Refractory Myeloma | Synapse
March 3, 2026
The Relationship of Baseline and Longitudinal Frailty and Inflammatory Biomarkers with CAR-T Treatment Outcomes in Relapsed Refractory Myeloma
Key Points
CAR-T treatment outcomes are influenced by baseline frailty and inflammatory biomarkers, suggesting a significant relationship.
Inflammatory biomarkers can serve as critical indicators of treatment effectiveness in relapsed refractory myeloma.
Longitudinal assessment highlights the importance of continuous monitoring of patient's frailty status during treatment.
Understanding these relationships may enable personalization of CAR-T therapies for better patient management.